Figure 5.
Figure 5. Mediators involved in the inhibitory function of CD11bhiIalo DCs. (A-B) CD11bhiIalo did not induce T-cell anergy (A) and the generation of Treg cells (B). GFP+ OVA323-339 peptide–specific CD4 T cells from (DO11.10 × GFP) F1 GFP+mice, stimulated by CD11bhiIalo for 7 days in the presence of OVA323-339 peptide (GFP+CD4), and naive GFP– OVA323-339 peptide–specific TCR CD4 T cells from (DO11.10 × GFP) F1 GFP– mice (GFP–CD4) were primed with mDCs in the presence of OVA323-339 peptide. On day 5, the proliferation of GFP–CD4 T cells and GFP+CD4 T cells (A) and the effect of GFP+CD4 T cells pretreated by CD11bhiIalo DCs on mDC-induced GFP–CD4 T-cell proliferation (B) were assayed by FACS. *P > .05. (C) CD4/mDC system was cocultured either with paraformaldehyde-fixed CD11bhiIalo DCs (CD11bhiIalo-fixed) or with 50% CD11bhiIalo DCs culture supernatant (CD11bhiIalo-SN). On day 5, viable peptide-specific CD4 T cells were tested by FACS. *P < .01, **P > .005. (D-E) Anti–IL-10 (5 μg/mL), and anti–TGF-β (5 μg/mL) neutralizing mAbs (D) and 1-methyltryptophan (1 mM), IDO inhibitor, and indomethacin (40 μM), PGE2 inhibitor (E) were added at the beginning of CD11bhiIalo/mDC/CD4 coculture. On day 5, viable peptide-specific CD4 T cells were tested by FACS. *P > .05. (F-G) The inhibitory function of CD11bhiIalo DCs was NO involved. Serious concentrations of NO donor NOC-18 (F) or serious concentrations of NOS inhibitor PBIT (G) were added into coculture system as indicated. On day 5, viable peptide-specific CD4 T cells were assayed by FACS. *P < .01. Data in panels represent mean ± SD of triplicate samples.

Mediators involved in the inhibitory function of CD11bhiIalo DCs. (A-B) CD11bhiIalo did not induce T-cell anergy (A) and the generation of Treg cells (B). GFP+ OVA323-339 peptide–specific CD4 T cells from (DO11.10 × GFP) F1 GFP+mice, stimulated by CD11bhiIalo for 7 days in the presence of OVA323-339 peptide (GFP+CD4), and naive GFP OVA323-339 peptide–specific TCR CD4 T cells from (DO11.10 × GFP) F1 GFP mice (GFPCD4) were primed with mDCs in the presence of OVA323-339 peptide. On day 5, the proliferation of GFPCD4 T cells and GFP+CD4 T cells (A) and the effect of GFP+CD4 T cells pretreated by CD11bhiIalo DCs on mDC-induced GFPCD4 T-cell proliferation (B) were assayed by FACS. *P > .05. (C) CD4/mDC system was cocultured either with paraformaldehyde-fixed CD11bhiIalo DCs (CD11bhiIalo-fixed) or with 50% CD11bhiIalo DCs culture supernatant (CD11bhiIalo-SN). On day 5, viable peptide-specific CD4 T cells were tested by FACS. *P < .01, **P > .005. (D-E) Anti–IL-10 (5 μg/mL), and anti–TGF-β (5 μg/mL) neutralizing mAbs (D) and 1-methyltryptophan (1 mM), IDO inhibitor, and indomethacin (40 μM), PGE2 inhibitor (E) were added at the beginning of CD11bhiIalo/mDC/CD4 coculture. On day 5, viable peptide-specific CD4 T cells were tested by FACS. *P > .05. (F-G) The inhibitory function of CD11bhiIalo DCs was NO involved. Serious concentrations of NO donor NOC-18 (F) or serious concentrations of NOS inhibitor PBIT (G) were added into coculture system as indicated. On day 5, viable peptide-specific CD4 T cells were assayed by FACS. *P < .01. Data in panels represent mean ± SD of triplicate samples.

Close Modal

or Create an Account

Close Modal
Close Modal